GPT and neutropenia: In the WJOG11418B NEWFLAME trial, nivolumab, abemaciclib plus endocrine therapy (cohort 1 fulvestrant or cohort 2 letrozole as endocrine backbone) was tested in a total of 16 patients, with ORR 50%, and the most common grade ≥ 3 treatment-related AEs (TRAEs) was neutropenia (7 (58.3%) and 3 (60.0%) in the fulvestrant and letrozole cohorts, respectively), followed by alanine aminotransferase elevation (5 (41.6%) and 4 (80.0%)).